Insider Transactions in Q4 2024 at C4 Therapeutics, Inc. (CCCC)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 07
2024
|
Andrew Hirsch President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,550
-2.44%
|
$33,300
$6.04 P/Share
|
|
Nov 07
2024
|
Andrew Hirsch President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+5.21%
|
-
|
|
Nov 07
2024
|
Jolie Siegel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,102
-1.91%
|
$6,612
$6.04 P/Share
|
|
Nov 07
2024
|
Jolie Siegel Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+6.11%
|
-
|
|
Nov 07
2024
|
Kelly Schick Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,102
-1.91%
|
$6,612
$6.04 P/Share
|
|
Nov 07
2024
|
Kelly Schick Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+6.11%
|
-
|
|
Nov 07
2024
|
Kendra Adams Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,102
-1.29%
|
$6,612
$6.04 P/Share
|
|
Nov 07
2024
|
Kendra Adams Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+4.2%
|
-
|
|
Nov 07
2024
|
Scott N Boyle Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,102
-1.91%
|
$6,612
$6.04 P/Share
|
|
Nov 07
2024
|
Scott N Boyle Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+6.11%
|
-
|
|
Oct 28
2024
|
Paige Mahaney Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
76,800
+50.0%
|
-
|
|
Oct 01
2024
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,023
+1.7%
|
$10,115
$5.56 P/Share
|
|
Oct 01
2024
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,474
+7.88%
|
$12,370
$5.56 P/Share
|